AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials
Javier Armisen, Mitra Rauschecker, Janeli Sarv, Mathias Liljeblad, Linda Wernevik, Mohammad Niazi, Jane Knöchel, Olof Eklund, Therése Sandell, James Sherwood, Linnéa Bergenholm, Stefan Hallén, Shan Wang, Prasad G. Kamble, Maria Bhat, Ingela Maxvall, Yixin Wang, Richard Lee, Sanjay Bhanot, Shuling Guo, Stefano Romeo, Eric Lawitz, Ola Fjellström, Daniel Lindén, Jenny E. Blau, Rohit Loomba
Topics & Concepts
Randomized controlled trialMedicineInternal medicinePhase (matter)ChemistryOrganic chemistryLiver Disease Diagnosis and TreatmentGrowth Hormone and Insulin-like Growth FactorsLiver Diseases and Immunity